Oct. 27th, 2015
HCC surveillance in an era of biomarkers

Doctor Robert G. Gish, a world renowned hepatologist, speaks about the importance of including biomarkers for HCC risk assessment in liver cancer surveillance programs and proposes his current liver surveillance algorithm as a model. To view the presentation:

Contact Us

Clinical Diagnostic and
Research Reagents:

HCC Biomarkers and
μTASWako® i30:

Phone: 877-714-1924

Wako is a comprehensive manufacturer of Clinical Diagnostic reagents that are of the highest quality and good value to performance. Our products are the result of nearly 90 years of dedication to the field of in vitro diagnostics.

WAKO Order Sheet

General Info

Product List

Product Detail


HCC Biomarkers

For Hepatocellular Carcinoma (HCC) Risk Assessment

Adding the two biomarkers, AFP-L3 and DCP, to your current HCC surveillance practice can increase your chances of detecting early HCC. These tests are available now through major reference laboratories in the United States and Canada.

For Health care professionals

For Laboratories

For Patients


Wako is a leading manufacturer of the highest quality chemistry reagents worldwide. Our products are the result of over 90 years of dedication to the field of laboratory science and research development. Our superior research reagents are easy to use and have a robust history of utilization in academia.

WAKO Order Sheet

General Info

Research Product List

Research Product Detail